Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Property, Plant & Equipment (Net)

Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Jun 2026

Property, plant & equipment (net) rises 3.8% from a year ago

Property, plant & equipment (net) stood at $567.32M at the end of Q2 FY2026, up 3.8% from a year earlier and up 1.5% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.

Context

  • Property, plant & equipment (net) amounted to 15.0% of total assets at the end of Q2 FY2026, down 0.9 pp from a year earlier.
  • Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.

What to watch

Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +3.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$567.32M+1.5% QoQ
Last fiscal yearDec 2025
$550.33M+5.1% YoY
Year agoJun 2025
$546.29M+3.8% since
Property, Plant & Equipment (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+5.1%——
3-year CAGR-2.3%——
5-year CAGR——
10-year CAGR——

Property, Plant & Equipment (Net) history

USD · from the balance sheet

Latest · FY2025
550.33M USD
Year-over-year change
+5.1%
4-year CAGR
-3.7%

Property, Plant & Equipment (Net) vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +3.8% is the 6th highest of 11, against a peer median of +4.2%.
  • Property, plant & equipment (net) amounts to 15.0% of total assets for AMRX, versus a peer median of 11.1%.
AMRX Competitors
Property, Plant & Equipment (Net) for AMRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹115.6B INR+3.2%+19.6%20.0%
TEVATeva Pharmaceutical Industries LimitedJun 2026$4.26B USD-17.6%-10.4%10.7%
VTRSViatris Inc.Jun 2026$2.7B USD-7.5%-4.2%7.7%
BHCBausch Health Companies Inc.Jun 2026$2.1B USD+5.2%+9.0%8.5%
PRGOPerrigo Company plcJun 2026$849M USD-22.7%-2.3%11.2%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$567.32M USD+3.8%-2.3%15.0%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$378.91M USD+7.1%+10.2%23.0%
EBSEmergent BioSolutions Inc.Mar 2026$199.4M USD-9.8%-37.4%15.1%
INDVIndivior Pharmaceuticals IncJun 2026$183M USD+20.4%+25.8%14.8%
ANIPANI Pharmaceuticals, Inc.Mar 2026$67.12M USD+15.4%+13.0%4.7%
CPIXCumberland Pharmaceuticals Inc.Mar 2026$7.86M USD+5.1%+16.1%11.1%
Peer median (excluding AMRX) —+4.2%+9.6%11.1%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents247.79M25.98M91.54M110.55M310.87M
Short-term Investments01.82M2.2M1.87M0
Net Receivables694.74M741.79M645.66M775.73M939.87M
Inventory489.39M530.74M581.38M612.45M606.3M
Other Current Assets41.95M64.37M7.57M40.7M4.44M
Total Current Assets1.52B1.41B1.38B1.59B1.91B
Property, Plant & Equipment (Net)639M589.36M550.14M523.69M550.33M
Goodwill593.02M598.85M598.63M597.44M595.47M
Intangible Assets1.17B1.1B890.42M732.38M563.5M
Long-term Investments085.59M37.09M35.92M7.82M
Tax Assets00000
Other Non-current Assets20.61M17.63M18.43M24.21M49.98M
Total Non-current Assets2.42B2.39B2.09B1.91B1.77B
Total Assets3.94B3.8B3.47B3.5B3.68B
Account Payables131.08M166.84M143.57M259.84M254.67M
Short-term Debt30.61M89.96M213.13M324.21M21.58M
Tax Payables2.52M0000
Deferred Revenue00398.41M00
Other Current Liabilities120.1M263.11M3.91M222.36M525.5M
Total Current Liabilities677.24M752.8M846.6M1.13B881.63M
Long-term Debt2.72B2.63B2.43B2.16B2.61B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65.43M97.12M41.77M163.33M75.79M
Total Non-current Liabilities2.9B2.84B2.56B2.42B2.79B
Total Liabilities3.57B3.59B3.41B3.55B3.67B
Common Stock3.01M3.04M3.07M3.1M3.15M
Retained Earnings(276.2M)(406.18M)(490.18M)(607.06M)(535.01M)
Accumulated OCI(24.83M)9.94M(32.35M)(65.51M)(110.73M)
Other Stockholders Equity00000
Minority Interest6.63M(89.49M)41.52M64.73M76.76M
Total Equity366.97M208.93M61.3M(44.54M)5.96M
Total Debt2.88B2.85B2.75B2.59B2.74B
Net Debt2.63B2.82B2.66B2.48B2.43B

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.